VistaGen fiscal Q3 net loss widens to $18.9 mln

Vistagen Therapeutics

12/02/2026 21:37

Overview

Biopharmaceutical firm's fiscal Q3 net loss widened to $18.9 mln

R&D expenses increased due to PALISADE Program for social anxiety disorder

Outlook

VistaGen implements cash preservation initiatives ahead of clinical milestones

Result Drivers

R&D EXPENSES - Increased R&D expenses due to higher research, development, and contract manufacturing costs for the PALISADE Program

CASH PRESERVATION - Implemented cash preservation initiatives to maintain strategic flexibility as clinical milestones approach

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.45
Q3 Net Income
-$18.90 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Vistagen Therapeutics Inc is $1.00, about 74.7% above its February 11 closing price of $0.57

Press Release: ID:nBw3NV4Yxa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)